Posted by Michael Wonder on 11 May 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics announce FDA approval of Elfabrio (pegunigalsidase alfa-iwxj) for the treatment of Fabry disease
10 May 2023 - PEGylated enzyme replacement therapy designed to provide long half-life.
Chiesi Global Rare Diseases and Protalix BioTherapeutics announced today that the US FDA has approved Elfabrio (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.
